Nilotinib Improves Motor Skills, Cognition and Autonomic Function in Open-Label Phase I Clinical Trial in Parkinsons Disease with Dementia and Lewy Body Dementia (I1.008)

Conclusions: These results indicate that Nilotinib is a potential therapy that can improve both motor and non-motor symptoms in PD. These data provide strong feasibility for multicenter, randomized, placebo-controlled, double blind trials in early PD and mild to moderate Alzheimers disease.Disclosure: Dr. Pagan has nothing to disclose. Dr. Valadez has nothing to disclose. Dr. Torres-Yaghi has nothing to disclose. Dr. Hebron has nothing to disclose. Dr. Falconer has nothing to disclose. Dr. Rogers has nothing to disclose. Dr. Mills has nothing to disclose. Dr. Helen has nothing to disclose. Dr. Wilmarth has nothing to disclose. Dr. Moussa has nothing to disclose.

Source: Neurology - April 3, 2016 Category: Neurology Authors: Pagan, F., Valadez, E., Torres-Yaghi, Y., Hebron, M., Falconer, R., Rogers, S., Mills, R., Helen, H., Wilmarth, B., Moussa, C. Tags: Redefining Parkinson ' s Disease: Novel Approaches to Understanding Its Mechanisms and Developing Treatments Data Blitz Presentations Source Type: research